Which CJC-1295 are you buying?
CJC-1295 is two molecules wearing one name. One carries a drug-affinity complex and lasted 5.8–8.1 days in the trial that measured it; the other has no complex and no half-life measured in people at all. That is the difference between a weekly injection and a nightly one, and not one listing read for this site says which is in the vial.
Where to buy either
ElitePhysiqMD
$315.00 per month
- What it is
- dose not stated
- What it buys
- Ipamorelin, with CJC-1295, with or without DAC not stated
- Read
- September 2026
Longevixx
$329 per month
- What it is
- dose not stated
- What it buys
- Ipamorelin, with CJC-1295, with or without DAC not stated
- Read
- September 2026
Two records, one name on the shelf
This site carries CJC-1295 (no DAC) and CJC-1295 + DAC as two separate records rather than one column, and the drawing below is the reason. They share a mechanism — both are recorded as GHRH analogs — and they do not share a dosing schedule.
One name. Two records. Same GHRH-analog backbone.
CJC-1295 (no DAC)
no attached complex
not reported in humans
no peer-reviewed human study reports one
Dominikowski et al. 2026
CJC-1295 + DAC
drug-affinity complex attached
5.8–8.1 days
Teichman et al. 2006
2 listings — form not stated
in neither record, because the seller does not say which one is in the box
One of these two has been timed in people and the other has not. CJC-1295 + DAC measured 5.8–8.1 days in an ascending-dose trial in healthy adults. For CJC-1295 (no DAC) the review that covers this exact compound reports not reported in humans, so there is no figure to set beside it and no multiple to quote.
0 of the 2 listings that name a CJC-1295 product say which form it contains. The rest are in neither record, drawn above as their own state — filing them under either one would assert the thing the seller withheld.
What the sellers actually list
2 of this site’s 19 priced listings name a CJC-1295 product. None say which form it contains. Both are sold as a pairing rather than on their own, so there is no figure on this site that buys either form of CJC-1295 by itself — which is why neither record has a price row anywhere.
- ElitePhysiqMD lists it as “CJC-1295 + Ipamorelin” at $315.00 per month, and the record carries the reason it cannot be filed: “CJC-1295, with or without DAC not stated”.
- Longevixx lists it as “CJC-1295 / Ipamorelin” at $329 per month, and the record carries the reason it cannot be filed: “CJC-1295, with or without DAC not stated”.
Read off each seller’s own page, September 2026. The full record for each is on its seller page, and every figure here, with its qualifier attached, is on the board on the home page.
One of them has been timed in people. The other has not
The DAC form has a number behind it. CJC-1295 + DAC measured 5.8–8.1 days in an ascending-dose trial in healthy adults, and it is printed as the span the trial reported rather than as a tidy midpoint nobody measured.
Note what that does not say. It does not say the shorter figure quoted around the internet is wrong. It says nobody has published the measurement — which is a stronger reason to keep the two records apart, not a weaker one.
What a listing that will not say leaves you with
A listing that names CJC-1295 and does not say which form is not filed under the likelier one. It is carried as its own state, in the data and on every page that renders it: it has its own bucket in the board’s filter, its own panel in the drawing above, and its own row in the census of what this site’s 14 seller records do not state.
The alternative would be to guess. Most of the market sells the no-DAC form in a nightly stack, so a guess would usually be right and would occasionally put a reader on a weekly injection schedule for a molecule they thought they were taking nightly. An unknown that is usually right is still an unknown, and this site would rather print a gap than a probable answer with no marker on it.
The head-to-head comparison of this molecule against the one this site is named for is on CJC-1295 vs sermorelin, and what the DAC form did in the trials that tested it in people is on what does CJC-1295 do.
Sources
Every pharmacological figure on this page comes from the document below. Seller figures are read off the seller’s own page and carry the date they were read.
2 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475. Read September 2026.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536. Read September 2026.